These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32975842)

  • 41. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
    Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Apr; 109(4):1025-1029. PubMed ID: 33521960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SARS-CoV-2 Infection Among People Living With HIV Compared With People Without HIV: Survey Results From the MACS-WIHS Combined Cohort Study.
    D'Souza G; Tong W; Gustafson D; Alcaide ML; Lahiri CD; Sharma A; French AL; Palella FJ; Kempf MC; Mimiaga MJ; Ramirez C; Kassaye S; Rinaldo CR; Brown TT; Tien PC; Adimora AA
    J Acquir Immune Defic Syndr; 2022 Jan; 89(1):1-8. PubMed ID: 34878431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
    Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
    AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV.
    Gidari A; Bastianelli S; Pierucci S; Busti C; Sabbatini S; Schiaroli E; Benedetti S; Gamboni G; Lanzi A; Francisci D
    Curr HIV Res; 2022; 20(4):296-300. PubMed ID: 35909272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
    Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of platelet-and endothelial-associated biomarkers of disease activity in people hospitalized with Covid-19 with and without HIV co-infection.
    van der Mescht MA; Steel HC; de Beer Z; Abdullah F; Ueckermann V; Anderson R; Rossouw TM
    Front Immunol; 2023; 14():1235914. PubMed ID: 37646024
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study.
    Inciarte A; Gonzalez-Cordon A; Rojas J; Torres B; de Lazzari E; de la Mora L; Martinez-Rebollar M; Laguno M; Callau P; Gonzalez-Navarro A; Leal L; Garcia F; Mallolas J; Mosquera M; Marcos MA; Ambrosioni J; Miro JM; Martinez E; Blanco JL;
    AIDS; 2020 Oct; 34(12):1775-1780. PubMed ID: 32773471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
    Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
    Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV.
    Amegashie EA; Asamoah P; Ativi LEA; Adusei-Poku M; Bonney EY; Tagoe EA; Paintsil E; Torpey K; Quaye O
    Exp Biol Med (Maywood); 2024; 249():10059. PubMed ID: 38628843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
    Berenguer J; Díez C; Martín-Vicente M; Micán R; Pérez-Elías MJ; García-Fraile LJ; Vidal F; Suárez-García I; Podzamczer D; Del Romero J; Pulido F; Iribarren JA; Gutiérrez F; Poveda E; Galera C; Izquierdo R; Asensi V; Portilla J; López JC; Arribas JR; Moreno S; González-García J; Resino S; Jarrín I
    Clin Microbiol Infect; 2021 Nov; 27(11):1678-1684. PubMed ID: 34186209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes.
    Sharov KS
    Int J Infect Dis; 2021 Jan; 102():163-169. PubMed ID: 33115677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dolutegravir: first global approval.
    Ballantyne AD; Perry CM
    Drugs; 2013 Sep; 73(14):1627-37. PubMed ID: 24052331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1.
    Levy I; Wieder-Finesod A; Litchevsky V; Biber A; Indenbaum V; Olmer L; Huppert A; Mor O; Goldstein M; Levin EG; Hod T; Cohen C; Lustig Y; Rahav G
    Clin Microbiol Infect; 2021 Dec; 27(12):1851-1855. PubMed ID: 34438069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
    Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
    [No Abstract]   [Full Text] [Related]  

  • 57. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
    Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
    AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.